Aldeyra Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 29 →Insiders3 insiders bought $522,600 in 3 open-market buys. No sales.→HoldersKnoll 9.1%AQR 6.2%Kingdon 4.4%→PeersClosest companies: PRLD, VTGN, FULC→
From the filings
Figures
- Net income
- −$23.1Mlast 12 months
- Operating cash flow
- −$26.0Mlast 12 months
- Cash and equivalents
- $45.1Mat the last balance sheet
- Total debt
- $0.00at the last balance sheet
- Shares outstanding
- 60.3M shareson issue